

Electronic Supplementary Information

for

Factors Affecting T Cell Responses Induced by Fully Synthetic Glyco Gold-Nanoparticles

Silvia Fallarini,¹ Tiziana Paoletti,¹ Carolina Orsi Battaglini,¹ Paolo Ronchi,² Luigi Lay,² Renato Bonomi,³ Satadru Jha,³ Fabrizio Mancin,³ Paolo Scrimin,^{*,3} and Grazia Lombardi^{*,1}


¹DISCAFF, University of “Piemonte Orientale Amedeo Avogadro”, Via Bovio 6, 28100 Novara, Italy

²Department of Organic and Industrial Chemistry and CISI and ISTM-CNR, University of Milano, Via Venezian 21, 20133 Milano, Italy

³Department of Chemical Sciences and ITM-CNR, University of Padova, Via Marzolo 1, 35131 Padova, Italy

Further Experimental Details

The Scheme for the preparation of the Fluorescein-tagged thiol (**iv**) is reported below.



Scheme. a: BOC (0.6 equiv), dioxane, rt, 12 h. b: 8-acetylsulfanyl-octanoic acid pentafluorophenyl ester (0.9 equiv), DIPEA (1.0 equiv), DCM, rt, 12 h. c: TFA/DCM (1:1), 0°C – rt, 30 min. d: 6 M HCl/EtOH (1:1), 60°C , 3 h. e: Fluorescein 5-isothiocyanate (0.9 equiv), DIPEA (1.63 equiv), THF, rt, 12 h.




Figure S1. Nanoparticle characterizations. (A) TEM image of **1/3** (the bar corresponds to 5 nm) and size distribution: average diameter = 1.8 ± 0.5 nm. (B) TEM image of **2/4** (the bar corresponds to 5 nm) and size distribution: average diameter = 4.9 ± 0.9 nm.




Figure S2. $^1\text{H-NMR}$ spectra. Diffusion filtered $^1\text{H-NMR}$ (300 MHz) spectra of the Au-NPs **1** and **2** (monosaccharide-coated) (A), and **3** and **4** (disaccharide-coated) (B) in D_2O , mixing time 0.2 sec, $T = 28\text{ }^\circ\text{C}$.




Figure S3. Characterization of 5 nm Glyco-Au-NPs by dynamic light scattering hydrodynamic diameter, top, and Z potentials, bottom, (Glyco-Au-NPs **2** in red, **4** in green)





Figure S4. Characterization of 5 nm Glyco-Au-NPs by therogravimetry; top: Glyco-Au-NPs **3** ; bottom: Glyco-Au-NPs **1**.




Figure S5: Glyco-Au-NPs ability to bind specific anti-MenA Ab. (A) Concentration-response curves of monosaccharide **8**, Glyco-Au-NPs **1** and **2** (left panel) or disaccharide **9**, Glyco-Au-NPs **3** and **4** (right panel) for the inhibition of the binding between MenA and the anti-MenA mouse polyclonal Ab evaluated by competitive ELISA. (B) The maximum inhibition elicited at 1 mg/ml by each compound in the ELISA. The concentration of each compound that produce the 50% of the maximum inhibition (IC₅₀). The data represent means ± SEM of five experiments run in triplicate.




Figure S6. A. Effects of the test compounds on apoptotic or necrotic cell death. Representative images include cell morphology (left panels), apoptotic cells stained with annexin V (green; middle panels), and necrotic cells stained with PI (red; right panels) after (24 h) treatment with saccharides **8** and **9** or Glyco-Au-NPs **1-4**. Images are representative of four different cell preparations. (Scale bar = 30 nm). B. Apoptotic and necrotic cells were counted under epifluorescence microscopy in six different fields of each sample. In all sample, the number of annexin V⁺ and PI⁺ cells were expressed as percentage over the total counted cells. The data represent means ± SEM of five experiments. Cells treated (2 h) with 0.5 mg/ml actinomycin D were considered as positive control of apoptosis, while TEG-functionalized Au-NPs **5** and **6** were used as Au-NP controls. *P_≤0.05; **P_≤0.01 versus compound-untreated cells (CTRL).




Figure S7. Glyco-Au-NPs activate macrophage effector functions. Effects of the test compounds on MHC II expression. FACS dot-plots show the expression of MHC II induced on RAW 264.7 cells by test compounds. Au-NPs **5** and **6** were used as Au-NP controls, while compound-untreated cells (CTRL) as negative controls. The y-axis represents fluorescence intensity.




Figure S8. T cell proliferation measured by FACS as reduction of CFSE fluorescence intensity due to cell division. Representative dot plots of CFSE-labelled T cells treated (6 days) with PHA (positive control), disaccharides **9**, Glyco-Au-NPs **3** and **4**.

[compound](μM)	Release IL-2 (pg/ml)					
	0	1×10^{-2}	1×10^{-1}	1×10^0	1×10^1	1×10^2
PHA	-	-	-	$386 \pm 18^{**}$	-	-
CTRL	12 ± 1.7	-	-	-	-	-
5	-	13 ± 2.5	14 ± 1.3	12 ± 1.9	15 ± 1.3	15 ± 2.3
6	-	14 ± 2.4	17 ± 1.8	15 ± 1.4	13 ± 1.4	13 ± 1.5
8	-	12 ± 2.2	15 ± 1.9	12 ± 1.7	18 ± 2.1	17 ± 1.3
1	-	13 ± 2.2	19 ± 1.5	13 ± 1.8	14 ± 2.2	15 ± 1.8
2	-	14 ± 1.9	13 ± 1.7	15 ± 2.1	19 ± 2.3	15 ± 1.8
9	-	8 ± 1.3	12 ± 2.4	14 ± 1.9	13 ± 2.2	15 ± 2.9
3	-	20 ± 3.5	$61 \pm 7.1^*$	33 ± 4.2	16 ± 5.1	12 ± 3.3
4	-	8 ± 2.3	$66 \pm 7.2^*$	$102 \pm 8.1^{**}$	$144 \pm 16.6^{**}$	$132 \pm 12.6^{**}$

Figure S9. Ability of test compounds to induce IL-2 release from activating T cells evaluated by ELISA. Data represent means \pm SEM of seven experiments run in triplicate. * $P \leq 0.05$; ** $P \leq 0.01$ vs. compound-untreated controls.